| Literature DB >> 35913539 |
Mohamed A Agour1, Ahmed A Hamed2, Mosad A Ghareeb3, Eman A A Abdel-Hamid4, Mohamed K Ibrahim5.
Abstract
This study was designed to evaluate the antimicrobial, antioxidant, and cytotoxic potentials of the marine actinomycetes spp. isolated from the Red Sea water, Hurghada, Egypt. Out of 80 actinomycetes isolates, one isolate AW6 was selected based on its antioxidant activity (IC50 about 5.24 µg/mL which scavenged 91% of formed DPPH free radicals) and antimicrobial potential against E. coli, S. aureus, B. subtilis, and P. aeruginosa, A. niger, and C. albicans. The strain was identified based on phenotypic and genotypic analysis, and deposited in the GenBank with accession number OK090864.1. Cultivation of the selected strain on rice, chromatographic purification, and structural elucidation led to the isolation of two compounds C1: umbelliferone, and C2: 1-methoxy-3-methyl-8-hydroxy-anthraquinone. The antimicrobial activity of the obtained compounds showed that C1 and C2 have low antibacterial activity toward S. aureus and E. coli with no pronounced activity toward P. aeruginosa, C. albicans, and A. niger. Additionally, the antioxidant activity of C1 and C2 revealed that C2 has a good antioxidant activity, with DPPH scavenging activity reaching (55.25%), followed by C1 (30.20%). Moreover, both compounds displayed anti-Gyr-B enzyme activity with IC50 value of (3.79 ± 0.21 µM) for C1, and (IC50 = 13 ± 0.71 µM) for C2. The ADME-related physicochemical properties of the obtained compound were predicted using SwissADME web tools and the ProToxii webserver was used to estimate in silico toxicity.Entities:
Keywords: ADME; Actinomyces sp. AW6; Anti-Gyr activity; Antimicrobial; Antioxidant; Secondary metabolites
Mesh:
Substances:
Year: 2022 PMID: 35913539 PMCID: PMC9343302 DOI: 10.1007/s00203-022-03092-5
Source DB: PubMed Journal: Arch Microbiol ISSN: 0302-8933 Impact factor: 2.667
Distribution and percent of actinobacteria isolated from different marine localities
| Location | Number of isolates | Percentage incidence (%) |
|---|---|---|
| Seawater Hurghada | 28 | 35 |
| RasSedr sediments | 24 | 30 |
| AinSokhna sediment | 20 | 25 |
| Marine algae | 8 | 10 |
| Total isolate | 80 | 100 |
Antimicrobial activity of actinobacterial crude extracts
| Extracts | Antibacterial activity (clear zone, mm) | Antifungal activity (clear zone, mm) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Gram + ve | |||||||||
| MRSA | |||||||||
| AW2 | NA | 10.8 ± 0.23 | NA | NA | 11.9 ± 0.45 | 9.9 ± 0.2 | NA | 10.9 ± 0.23 | NA |
| AW 6 | 17.6 ± 0.24 | 23.8 ± 0.34 | 21.8 ± 0.12 | 17.8 ± 0.2 | 25.7 ± 0.3 | 22.3 ± 0.4 | 17.6 ± 0.24 | 23.7 ± 0.34 | 9.2 ± 0.10 |
| AR3 | NA | 13.2 ± 0.52 | NA | NA | NA | NA | 10.3 ± 0.13 | 13.2 ± 0.52 | NA |
| AR10 | 9.7 ± 0.13 | NA | NA | NA | 9.1 ± 0.18 | NA | 9.9 ± 0.13 | NA | NA |
| B 9 | NA | NA | NA | NA | NA | 12.7 ± 0.23 | 11.3 ± 0.43 | NA | |
| B 10 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| B 11 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Strep: | 17.2 ± 0.10 | 24. 6 ± 0.20 | 20.0 ± 0.31 | 23.2 ± 0.12 | 25.3 ± 0.19 | 23.8 ± 0.31 | – | – | – |
| Amp: | – | – | – | – | – | – | 22.9 ± 0.12 | 25.3 ± 0.19 | 9.6 ± 0.31 |
Each value in the table is the mean ± standard deviation of three trials
NA not active, Strep. Streptomycin, Amp amphotericin B
Fig. 1Phylogenetic tree of the Actinomyces sp. AW6
Fig. 2Isolated compounds from Actinomyces sp. AW6
MIC of the isolated compounds (C1 and C2), the antibiotic streptomycin and the antifungal fluconazole
| Compounds | MIC (µg/mL) | ||||
|---|---|---|---|---|---|
| Compound 1 | 125 | 250 | – | – | – |
| Compound 2 | 125 | 125 | – | – | – |
| Streptomycin | < 0.78 | 6.25 | 25 | – | – |
| Amphotericin B | – | – | – | 0.50 | 5.00 |
DPPH scavenging activity of compounds C1 and C2
| Compounds | DPPH scavenging activity (%) | IC50 (µg/mL) |
|---|---|---|
| Umbelliferone (C1) | 30.20 | 5.47 |
| 1-methoxy-3-methyl-8-hydroxy anthraquinone (C2) | 55.25 | 3.84 |
| Ascorbic acid | 78.50 | – |
Fig. 3DNA Gyrase-B inhibition activity of the obtained compounds C1 and C2
ADME-related physicochemical parameters of dibutyl phthalate ester
| Predictive models parameters | Compound 1 | Compound 2 | |
|---|---|---|---|
| Physicochemical Properties | Molecular Weight | 162.14 | 268.26 |
| Fraction Csp3 | 0.00 | 0.12 | |
| Rotatable bonds | 0 | 1 | |
| H-bond acceptors | 3 | 4 | |
| H-bond donors | 1 | 1 | |
| Molar Refractivity | 44.51 | 73.23 | |
| Topological polar surface area (TPSA) | 50.44 Å2 | 63.60 Å2 | |
| Lipophilicity | log | 1.58 | 3.40 |
| log | 1.50 | 2.48 | |
| log | 1.04 | 1.17 | |
| Solubility | log | − 2.46 | − 4.02 |
| Solubility | 5.66e–01 mg/mL; 3.49e–03 mol/L | 2.54e–02 mg/mL; 9.48e–05 mol/L | |
| Class | Soluble | Moderately soluble | |
| Druglikeness | Lipinski (RO5) | Yes; 0 violation | Yes; 0 violation |
| Ghose | No; 1 violation: #atoms < 20 | Yes | |
| Veber | Yes | Yes | |
| Bioavailability Score | 0.55 | 0.55 | |
| Leadlikness | Rule of three (RO3) | No; 1 violation: MW < 250 | Yes |
| Synthetic accessibility | 2.56 | 2.57 | |
| Pharmacokinetics Parameters | GI (HIA) absorption | High | High |
| BBB permeant | Yes | Yes | |
| P-gp substrate | No | No | |
| CYP1A2 inhibitor | Yes | Yes | |
| CYP2C19 inhibitor | No | Yes | |
| CYP2C9 inhibitor | No | Yes | |
| CYP2D6 inhibitor | No | No | |
| CYP3A4 inhibitor | No | Yes | |
| log | − 6.17 cm/s | − 5.52 cm/s | |
log Po/w = The partition coefficient between n-octanol and water, log S = The decimal logarithm of the molar solubility in water. Lipinski (RO5) criteria range are lipophilicity (log Po/w) ≤ 5, MW ≤ 500, H-bond donors ≤ 5, and H-bond acceptors ≤ 10. Ghose filter criteria range is log Po/w in − 0.4 to + 5.6 range, MR from 40 to 130, MW from 180 to 480, No. of atoms from 20 to 70. Veber rule criteria range are: RB ≤ 10 and TPSA ≤ 140 Å2. RO3 criteria range is XLOGP3 ≤ 3.5, MW ≤ 350, H-bond donors ≤ 3, H-bond acceptors ≤ 3, and RB ≤ 3. Synthetic accessibility (SA) score ranges from 1 (very easy) to 10 (very difficult)
GI (HIA) human gastrointestinal absorption, BBB Blood–brain barrier permeation, P-gp permeability glycoprotein, log K the skin permeability coefficient
Fig. 4Bioavailability Radar plot of a compound 1 and b compound 2. The pink area shows the optimal range for each property (Lipophilicity: XLOGP3 between − 0.7 and + 5.0, size: MW between 150 and 500 g/mol, polarity: TPSA between 20 and 130 Å2, solubility: log S not higher than 6, saturation: fraction of carbons in the sp3 hybridization not less than 0.25, and flexibility: no more than 9 rotatable bonds) (color figure online)
Fig. 5BOILED-Egg plot for both C1 and C2. The yellow zone (yolk) is for highly possible BBB permeability, while the white region (GI) is for highly probable HIA (GI) absorption. Molecules with minimal absorption and no brain penetration are represented by the outside gray zone. The points are also colored blue if P-gp substrate (PGP +) is expected, and red if P-gp non-substrate (PGP) is projected (color figure online)
In silico toxicity prediction of purified compounds (C1 and C2)
| Classification | Target | C1 | C2 |
|---|---|---|---|
| Organ toxicity | Hepatotoxicity | Inactive | Inactive |
| Toxicity end points | Carcinogenicity | Active | Inactive |
| Immunotoxicity | Inactive | Active | |
| Mutagenicity | Inactive | Active | |
| Cytotoxicity | Inactive | Inactive | |
| Tox21-Nuclear receptor signaling pathways | Aryl hydrocarbon Receptor (AhR) | Inactive | Active |
| Androgen Receptor (AR) | Inactive | Inactive | |
| Androgen Receptor Ligand Binding Domain (AR-LBD) | Inactive | Inactive | |
| Aromatase | Inactive | Inactive | |
| Estrogen Receptor Alpha (ER) | Inactive | Active | |
| Estrogen Receptor Ligand Binding Domain (ER-LBD) | Inactive | Inactive | |
| Peroxisome Proliferator Activated Receptor Gamma (PPAR-Gamma) | Inactive | Inactive | |
| Tox21-Stress response pathways | Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE) | Inactive | Inactive |
| Heat shock factor response element (HSE) | Inactive | Inactive | |
| Mitochondrial Membrane Potential (MMP) | Inactive | Active | |
| Phosphoprotein (Tumor Supressor) p53 | Active | Inactive | |
| ATPase family AAA domain-containing protein 5 (ATAD5) | Inactive | Inactive |